When it comes to gene sequencing and personalized medicine for cancer, spotting an aberrant kinase is a home run. The proteins are relatively easy to target with drugs and plenty of kinase inhibitors already exist. Now in a new study, University of Michigan Comprehensive Cancer Center researchers assess the complete landscape of a cancer’s “kinome” expression and determine which kinases are acting up in a particular tumor. They go on to show that those particular kinases can be targeted with drugs -- potentially combining multiple drugs to target multiple kinases.
